Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5092072 | 0.86 | HPGD (0.55) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL3723155 | 0.83 | CYP1A2 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL5336038 | 0.83 | SMN1; SMN2 (0.49) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL25230614 | 0.83 | MAPT (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL8894385 | 0.83 | ALDH1A1 (0.71) | ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL14543377 | 0.79 | ALDH1A1 (0.53) | ALDH1A1TSHRMAPTKDM4EMAPK1 | |
| SCHEMBL12932481 | 0.79 | SMN1; SMN2 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL13999757 | 0.78 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL29512567 | 0.78 | TSHR (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL29512760 | 0.78 | TSHR (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725419-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20130210814-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8410093-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20110152518-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-7868013-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7858633-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7754714-B2 | (1S, 2R)-N4-(2-Aminocarbonylcyclopent-1-yl)-5-fluoro-N2-[4-(4-methylpiperazin-1-yl)-3-methylphenyl]-2,4-pyrimidinediamine, having antiproliferative activity, used to inhibit cellular proliferation and to treat proliferate diseases such as cancers | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7511137-B2 | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates | RIGEL PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1763514-A2 | CYCLOALKYL SUBSTITUTED PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1694652-A1 | STEREOISOMERS AND STEREOISOMERIC MIXTURES OF 1-(2,4-PYRIMIDINEDIAMINO)-2-CYCLOPENTANECARBOXAMIDE SYNTHETIC INTERMEDIATES | Rigel Pharmaceuticals, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060035891-A1 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | MIDCAP FINANCIAL TRUST | 2006-02-16 | — | — | US | disclosed |
| WO-2005118544-A2 | CYCLOALKYL SUBSTITUTED PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050192301-A1 | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates | MIDCAP FINANCIAL TRUST | 2005-09-01 | — | — | US | disclosed |
| WO-2005063722-A1 | STEREOISOMERS AND STEREOISOMERIC MIXTURES OF 1-(2,4-PYRIMIDINEDIAMINO)-2-CYCLOPENTANECARBOXAMIDE SYNTHETIC INTERMEDIATES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152518-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | ALDH1A1 1807/4885CYP1A2 4549/4885CYP2C9 4708/4885 |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | ALDH1A1 1807/4885CYP1A2 4549/4885CYP2C9 4708/4885 |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | ALDH1A1 1807/4885CYP1A2 4549/4885CYP2C9 4708/4885 |
| US-20050192301-A1 | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates | PCNA, PAICS, DPYD | ALDH1A1 1230/4885CYP1A2 742/4885CYP2C9 1909/4885 |
| US-20060035891-A1 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | MKI67, PCNA, TK1 | ALDH1A1 1807/4885CYP1A2 4549/4885CYP2C9 4708/4885 |
| US-20130210814-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | ALDH1A1 1807/4885CYP1A2 4549/4885CYP2C9 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.